The effect of alpha1-AR antagonists for lower urinary tract symptoms in patients undergoing prostate 125I brachytherapy for prostate carcinoma

The effect of alpha1-AR antagonists for lower urinary tract symptoms in patients undergoing prostate 125I brachytherapy for prostate carcinoma - Efficacy of alpha1-AR antagonists in patients undergoing brachytherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005786

Enrollment

160

Registered

2011-06-16

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

8 mg silodosin daily control group

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Pathologically proven prostate cancer. Patient who underwent prostate brachytherapy or prostate brachyterapy in combination with external beam radiation therapy. Written informed consent can be obtained.

Exclusion criteria

Exclusion criteria: Patient with allergy against Silodocin. Patient with neurogenic bladder, bladder neck constructure, urethral stenosis, vesical stone, or large bladder diverticulum. Patient with active urinary tract infection. Patient with severe renal dysfunction. Patient with severe liver disease. Patient who is considered to be inapropriate for this study by physisian.

Design outcomes

Primary

Measure	Time frame
IPSS total score	—

Secondary

Measure	Time frame
Pressure flow study, I-PSS storage subscores, I-PSS voiding subscores ,QOL, OABSS, IIEF5, Uroflowmetry, PVR	—

Countries

Japan

Contacts

Public ContactNobutaka SHIMIZU

Kinki University Faculty of Medicine Department of Urology

shimizun@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026